The following LIMR-developed IP and technologies are available for licensing. To learn more, please contact LIMR at 484.476.8000 or email info@limr.org.

Cancer

Targeted nano-carrier therapeutics for precision medicine

Principal investigator: Janet Sawicki, PhD

Taking a new precision medicine approach, LIMR researchers have developed a safe and effective nanocarrier-based therapy that specifically targets ovarian tumor cells and blocks a central mechanism of drug resistance (siHuR-3DNA). Preclinical proof of concept suggests that targeting this mechanism via this nanocarrier agent may offer safe and effective treatment of a variety of solid tumors exhibiting drug resistance.

Polyamine-blocking therapeutics activate the immune system to block tumor growth

Principal investigator: Susan Gilmour, PhD

Recent work by two leaders in the field, including LIMR Deputy Director Susan Gilmour, PhD, has led to the discovery of drug-based strategies to target the upregulated polyamine-transport system in tumors. In preclinical studies, these strategies safely and effectively kill tumor cells, either directly, with polyamine-conjugated cytotoxic drugs, or indirectly, by reversing local tumoral immunosuppression and activating effective anti-tumor immunity.

Combination therapy using IDO inhibitors to eliminate tumor vasculature

Principal investigator: Alexander Muller, PhD

LIMR’s technology encompasses new uses of IDO inhibitors to enhance the activity of anti-angiogenic or antimetabolic drugs used to treat cancer or in other disease settings where ablation of a pathogenic blood vasculature is desired.

Blood test to predict risk of chemotherapy-induced nausea

Principal investigator: U. Margaretha Wallon, PhD

Nausea after chemotherapy is a much-feared side effect. Yet not all patients experience it to the same degree, or even at all. Dr. Wallon developed a blood-based assay that can predict which patients will experience post-chemotherapy nausea. With that information, physicians can prescribe the right dosage of antiemetics to the right patients at the right time for a truly precision-medicine approach to patient treatment.

IDO/TDO pro-drug inhibitors

Principal investigator: Alexander J. Muller, PhD and George C. Prendergast, PhD

LIMR’s collaborative team has created the first pro-drug class of small molecule inhibitors that can be tuned to inhibit various subsets of the known IDO/TDO enzymes, representing new structure of matter for clinical development.


Autoimmune disease

Treatment of autoimmune disorders with RhoB antibodies

Principal investigators: Lisa Laury-Kleintop, PhD and Laura-Mandik-Nayak, PhD

Building on long-standing studies of the disease-promoting small GTPase RhoB, including in selectively driving production of autoantibodies, LIMR scientists have developed a cell-permeable anti-RhoB antibody that exhibits therapeutic efficacy in preclinical models of rheumatoid arthritis, lupus and diabetes. In principle, this invention affords a general strategy for treating autoimmune disorders driven by autoantibody production as a single class by administering a single biologic agent directed against a nodal signal transduction modifier. LIMR’s innovative approach incorporates the leading edge in targeting intracellular antigens generally considered inaccessible to antibody-based therapies.

Treatment of inflammatory bowel disease with Bin1 antibodies

Principal investigator: Sunil Thomas, PhD

Building on their expertise in tissue barrier functions of the gastrointestinal tract, LIMR scientists have now developed an antibody-based therapy that inactivates a molecule that facilitates gut inflammation in the setting of IBD.

Treatment of rheumatoid arthritis and autoimmune disorders with IDO2 antibodies

Principal investigator: Laura Mandik-Nayak, PhD and Lisa Laury-Kleintop, PhD

The immunomodulatory enzyme IDO2, discovered by LIMR scientists, has been identified as an essential mediator of autoimmune disease. In preclinical models of rheumatoid arthritis (RA), systemic administration with a cell-permeable monoclonal antibody developed at LIMR that specifically binds IDO2 in B cells reduced the level of autoreactive T and B cell activation and alleviated pathogenic symptoms. LIMR’s investigators have defined a pathway that allows for effective targeting of intracellular antigens previously considered inaccessible to antibody-based therapies.


Gastrointestinal

Blood test to distinguish inflammatory bowel disease from inflammatory bowel syndrome

Principal investigator: Thomas Stamato, PhD

With no well-established standards to accurately diagnose IBD, there is a need for biomarkers that are cost-effective, rapid and provide insight into individual disease complexity and biology. In addressing the need for a non-invasive assessment of IBD in patients presenting with IBS, LIMR scientists have developed a blood test that may make this determination as an aid to improving personalized care.


Infectious diseases

Anti-rabies human monoclonal antibody

Lead investigator: Scott Dessain, PhD, MD

LIMR cloned six human monoclonal antibodies (huMabs) from individuals infected with rabies, and in preclinical studies efficiently cleared the infection. These huMabs offer an opportunity for a novel passive vaccine to clear the rabies virus in infected patients.

New approach for drug-resistant topical infections

Principal investigators: George C. Prendergast, PhD, and Melvin Reichman, PhD

Building on concepts developed at LIMR to treat cancer by relieving immunosuppression in the local tumor microenvironment, our researchers have designed an antimicrobial formulation to treat infections by relieving immune barriers imposed by the local microbial ecology in which the infectious agent is embedded.

Prevention and clearance of drug-resistant bacteria

Lead investigator: Scott Dessain, PhD, MD

LIMR has generated a unique patient-derived human monoclonal antibody (huMab) that recognizes a universal structural feature present in all amyloid proteins in nature. This huMab could offer a way to prevent and clear any strain of drug-resistant bacteria found on clinical tubing or device surfaces.


Monoclonal antibody cloning

Human monoclonal antibody display technology

Principal investigator: Scott Dessain, MD, PhD

The Center for Human Antibody Technology (CHAT) is a facility at LIMR that uses a powerful human antibody cloning platform technology developed by Dr. Scott Dessain. CHAT uses this platform along with a state-of-the-art, high throughput antibody production and screening facility to produce human antibodies cloned from patients to diagnose, prognose or treat infectious disease, cancer or neurological illnesses. LIMR’s technology makes development of human monoclonal antibodies by biotechnology companies easier and more efficient.


Neurological disorders

Anti-amyloid huMab for Alzheimer's disease

Lead investigator: Scott Dessain, PhD, MD

Medical advances paralleling aging demographics in developed countries have created an unprecedented need for strategies to prevent and treat dementia, especially late-onset Alzheimer’s disease (AD). The role of amyloid deposition is well established in AD etiology. The amyloid protein Aß is a therapeutic target for immunological clearance in AD.

Diagnostic agent for autoimmune brain encephalitis

Lead investigator: Scott Dessain, PhD, MD

LIMR’s human monoclonal antibody can detect membrane-bound forms of the NMDA receptor, thus enabling clinicians to reliably diagnose the autoimmune disease anti-NMDA receptor encephalitis, a serious psychiatric disorder.


Ocular diseases

Novel treatments for macular degeneration

Lead investigators: Lisa Laury-Kleintop, PhD, and Alexander J. Muller, PhD

LIMR researchers have defined new medicinal uses for two classes of drugs that could treat ocular diseases such as wet macular degeneration, diabetic retinopathy, macular edema, diabetic macular edema, and myopic choroidal neovascularization.